Imaging SV2A in mood disorders
Mental Health & Behavioral Research
What is the purpose of this trial?
The goal of the study is to determine whether there are alterations in synaptic vesicle glycoprotein 2A (SV2A), a protein expressed ubiquitously in synaptic vesicles, in depression and anxiety and whether ketamine, an N-Methyl-D-aspartate (NMDA) antagonist, normalizes SV2A density at time of its greatest anti-depressant response. We will conduct an examination of SV2A and associated consequences using neuroreceptor imaging and behavioral techniques.
- Ages18 years - 70 years
- Trial withYale University School of Medicine
- Start Date03/19/2016
- End Date03/15/2022
- Last Updated07/15/2021
- Study HIC#1511016789